Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-05
2011-07-05
Olson, Eric S (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S405000, C514S427000, C514S220000, C514S259410, C540S557000, C544S405000, C548S561000
Reexamination Certificate
active
07973043
ABSTRACT:
The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such as a selective serotonin reuptake inhibitor, as initial treatment or as soon as possible. The method targets the prevention of suicide, and provides other benefits including preventing disease progression development of tolerance toward the antidepressants. Another aspect of the invention relates to using the method for alleviating cognitive distortion and related functional impairment or health risks, and/or using the method for smoking cessation or nicotine withdrawal.
REFERENCES:
patent: 4310524 (1982-01-01), Wiech et al.
patent: 5500343 (1996-03-01), Blum et al.
patent: 5589512 (1996-12-01), Norden
patent: 5591884 (1997-01-01), DeNinno et al.
patent: 5780051 (1998-07-01), Eswara et al.
patent: 5958921 (1999-09-01), Tollefson
patent: 6066643 (2000-05-01), Perry
patent: 6121259 (2000-09-01), Yelle
patent: 6147072 (2000-11-01), Bymaster et al.
patent: 6159963 (2000-12-01), Beasley et al.
patent: 6174882 (2001-01-01), Yelle
patent: 6322503 (2001-11-01), Sparhawk, Jr.
patent: 6348455 (2002-02-01), Yelle
patent: 6352984 (2002-03-01), Yelle
patent: 6395727 (2002-05-01), Guadagno et al.
patent: 6399608 (2002-06-01), Dawson
patent: 6582737 (2003-06-01), Hirsh et al.
patent: 6960577 (2005-11-01), Tollefson
patent: 2001/0048943 (2001-12-01), Faour et al.
patent: 2002/0016325 (2002-02-01), Taylor
patent: 2002/0035145 (2002-03-01), Tsai et al.
patent: 2002/0040041 (2002-04-01), Taylor
patent: 2002/0051807 (2002-05-01), Faour et al.
patent: 2002/0123490 (2002-09-01), Howard, Jr.
patent: 2003/0049308 (2003-03-01), Theobald et al.
patent: 0958824 (1999-11-01), None
patent: 0958824 (1999-11-01), None
patent: 0966967 (1999-12-01), None
patent: 1238676 (2002-09-01), None
patent: WO 95/00154 (1995-01-01), None
patent: WO 99/58130 (1999-11-01), None
patent: WO 99/61027 (1999-12-01), None
patent: WO 01/51040 (2001-07-01), None
patent: WO 01/51041 (2001-07-01), None
patent: WO01/80837 (2001-11-01), None
patent: WO 02/053140 (2002-07-01), None
patent: WO02/060423 (2002-08-01), None
U.S. Appl. No. 10/001,827, filed Jul. 2002, Chappell et al.
George, t. et al. “A Placebo-Controlled Trial of Bupropion for Smoking Cessation in Schizophrenia” (2002) Biological Psychiatry, vol. 52, pp. 53-61.
Kelleher et al., “Advances in Atypical Antipsychotics for the Treatment of Schizophrenia” CNS Drugs (2002) vol. 16, No. 4, pp. 249-261.
Berman et al., “Antidepressant Effects of Ketamine in Depressed Patients,” Biological Psychiatry (2000) vol. 47, pp. 351-354.
Robertson et al., “Major Tranquilizers Used as Antidepressants” Journal of Affective Disorders (1982) vol. 4, pp. 173-193.
Chemical Abstracts Registry entry No. 129722-12-9 (aripiprazole), entered into STN on Oct. 5, 1990.
The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, published 1999 by Merck Research Laboratories, ed. by Beers and Berkow, pp. 1531-1538 and 1569-1570.
Pivac et al., “Collegium Internationale Neuro-Psychopharmacologicum” Psychiatria Danubina (2002) vol. 14, No. 3-4, pp. 231-242.
Roth et al., “D4 Dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs,” Psychopharmacology (1995) vol. 120, pp. 365-368.
Schmidt et al., “Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile” European Journal of Pharmacology (2001) vol. 425, pp. 197-201.
American Academy of Pediatrics, Committee on Nutrition, “The Use and Misuse of Fruit Juice in Pediatrics” Pediatrics (2001) vol. 107, No. 5, pp. 1210-1213.
Casey et al., “An integrated cognitive model of panic disorder: The role of positive and negative cognitions” Clinical Psychology Review (2004) vol. 24 pp. 529-555.
WHfoods, “Is Fruit Juice as good as whole fruit” published online at http://www.whfoods.com/genpage.php?tname=george&dbid=74.
Ost et al., “Probability ratings in claustrophobic patients and normal controls” Behavior Research and Therapy (2000) vol. 38 pp. 1107-1116.
Tang et al., PNU-96415E, a Potential Antipsychotic Agent with Clozapine-Like Pharmacological Properties The Journal of Pharmacology and Experimental Therapeutics (1997) vol. 281, pp. 440-447.
Uhlenhuth et al., “The revised Anxious Thoughts and Tendencies (AT&T) scale: a general measure of anxiety-prone cognitive style” Journal of Affective Disorders (1999) vol. 52, pp. 51-58.
WHfoods, “Is Fruit Juice as good as whole fruit” published online at http://www.whfoods.com/genpage.php?tname=george&dbid=74 Aug. 25, 2008.
Michael E. Thase, M.D.; “What Role Do Atypical Antipsychotic Drugs Have in Treatment-Resistant Depression?”; The Journal of Clinical Psychiatry; Feb. 2002; pp. 95-103; 63:2; Physicians Postgraduate Press, Inc., Memphis, Tennessee.
Jambur Ananth; “Treatment-Resistant Depression”; Psychother Psychosom; 1998; pp. 61-70; 67; S. Karger AG, Basel, Switzerland.
D. Souery et al.; “Treatment resistant depression: methodological overview and operational criteria”; European Neuropsychopharmacology; 1999; pp. 83-91; 9; Elsevier Science B.V./ECNP; Amsterdam, The Netherlands.
Mark W. Viner, M.D. et al.; “Low-dose Risperidone Augmentation of Antidepressants in Nonpsychotic Depressive Disorders with Suicidal Ideation”; Journal of Clinical Psychopharmacology; Feb. 2003; pp. 104-106: vol. 23. No. 1; Lippincott Williams & Wilkins; Philadelphia, Pennsylvania.
De Adson, M.D. et al.; “An Open Trial of Quetiapine for Anxiety in Patents Receiving an SSRI”; Society of Biological Psychiatry Annual Meeting; May 16-18, 2002; Philadelphia, Pennsylvania.
Shigehiro Hirose, M.D. and Charles R. Ashby, Jr., Ph.D.; “An Open Pilot Study Combining Risperidone and a Selective Serotonin Reuptake Inhibitor as Initial Antidepressant Therapy”; Journal of Clinical Psychiatry; Aug. 2002; pp. 733-736; 63:8; Physicians Postgraduate Press, Inc., Memphis, TN.
Evins at al. Buproprion and smoking cessation (Am. J. Psychiatry 156:5, May 1999 pp. 798-799.).
Beasely CM et al Olanzapine versus placebo and Haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14: 111-123 1996.
Tollefson GD et al (1998a) Depressive signs and symptoms in Schizophrenia. A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250-258.
Tollefson GD et al (1998b) A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998; 43:803-810.
Azhar MZ Comparison of fluvoxamine alone, fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan—implications for management by family doctors. Med J Malaysia 2000 55(4)402-8.
Barlow DH Anxiety and its disorders (learned alarms) pp. 220-225, Guilford Press,1988.
Brody A. et al Regional brain metabolic changes in patients with major depression treated with either paroxetine or Interpersonal therapy. Arch Gen Psychiatry 2001; 58:631-640.
Cremers TI, et al Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism? Biol Psychiatry Jul. 1, 2001; 50(1):13-21.
Current Patents Nov. 15, 2002 week 0246 at http://scientific.thompson.com/media/cdjournals/gazettenews/202/CPG—News—0246.pfd-enclosed.].
DeRubeis RJ et al Cognitive therapy vs Medications in the treatment of moderate to severe depression Arch Gen Psychiatry 2005; 62:409-416.
Ferris RM et al Buproprion: a new antidepressa
LandOfFree
Combination therapy for depression, prevention of suicide,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for depression, prevention of suicide,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for depression, prevention of suicide,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699101